November 17, 2016 - By Hazel Jackson · 0 Comments
The stock of TG Therapeutics Incorporated (NASDAQ:TGTX) registered an increase of 3.83% in short interest. TGTX’s total short interest was 7.44 million shares in November as published by FINRA. Its up 3.83% from 7.16M shares, reported previously. With 263,900 shares average volume, it will take short sellers 28 days to cover their TGTX’s short positions. The short interest to TG Therapeutics Incorporated’s float is 27.36%. About 304,238 shares traded hands. TG Therapeutics Inc (NASDAQ:TGTX) has declined 44.77% since April 15, 2016 and is downtrending. It has underperformed by 49.39% the S&P500.
TG Therapeutics, Inc. is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The company has a market cap of $310.59 million. The Firm is developing over two therapies targeting hematological malignancies. It currently has negative earnings. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.09, from 1.45 in 2016Q1. The ratio improved, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Moreover, Credit Suisse Ag has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 192,336 shares. State Common Retirement Fund accumulated 0% or 223,851 shares. Ubs Asset Americas Inc holds 0.01% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 1.81M shares. Teachers has 0% invested in the company for 56,545 shares. Wells Fargo Mn has 0% invested in the company for 18,375 shares. Barclays Public Limited Com accumulated 41 shares or 0% of the stock. Eventide Asset Mgmt Limited Liability has 0.2% invested in the company for 537,600 shares. Jpmorgan Chase Co holds 0% or 157 shares in its portfolio. Bancorporation Of America De reported 10,484 shares or 0% of all its holdings. Pnc Fincl Service Grp holds 0% or 2,810 shares in its portfolio. Bancorp Of New York Mellon Corporation accumulated 176,637 shares or 0% of the stock. Moreover, Blackrock Investment Management Ltd has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 149,087 shares. Tower Capital Ltd Limited Liability Company (Trc) accumulated 3,882 shares or 0% of the stock. Pictet Asset Mngmt Limited has 0.04% invested in the company for 1.22 million shares. Mariner Wealth Advsrs Ltd Co last reported 19,086 shares in the company.
Insider Transactions: Since July 5, 2016, the stock had 0 insider buys, and 1 insider sale for $302,052 net activity. The insider Power Sean A sold $302,052.
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Tuesday, December 1 by FBR Capital. Zacks upgraded TG Therapeutics Inc (NASDAQ:TGTX) on Wednesday, August 12 to “Hold” rating. The rating was reinitiated by H.C. Wainwright on Wednesday, August 12 with “Buy”. On Thursday, October 6 the stock rating was reinitiated by Brean Capital with “Buy”. The stock has “Buy” rating given by SunTrust on Friday, May 27. The company was initiated on Wednesday, September 9 by Raymond James. The company was initiated on Friday, May 27 by Suntrust Robinson.
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
More important recent TG Therapeutics Inc (NASDAQ:TGTX) news were published by: Fool.com which released: “Why TG Therapeutics, Inc. Stock Is Dropping Today” on October 13, 2016, also Prnewswire.com published article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …”, Globenewswire.com published: “TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2016 Financial …” on October 31, 2016. More interesting news about TG Therapeutics Inc (NASDAQ:TGTX) was released by: Globenewswire.com and their article: “TG Therapeutics, Inc. Announces Publication in Blood Describing a Novel …” with publication date: October 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson